Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model

Neoplasia

Volumn 9, Issue 7, 2007, Pages 546-555

  Ferrier, Moira C ^a   Sarin, Hemant ^a   Fung, Steve H ^a   Schatlo, Bawarjan ^a,b   Pluta, Ryszard M ^a   Gupta, Sandeep N ^c   Choykeb, Peter L ^d   Oldfield, Edward H ^a   Thomasson, David ^a   Butman, John A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c General Electric Medical Systems   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti angiogenesis; Blood brain barrier; Tumor permeability

Indexed keywords

2 AMINO 2 METHYLPROPIONIC ACID; 2 AMINO 2 METHYLPROPIONIC ACID CARBON C 14; CARBON 14; GADOLINIUM PENTETATE; ISOFLURANE; POLYETHYLENE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN TUMOR; CANCER TRANSPLANTATION; CANNULATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; FISCHER 344 RAT; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RAT STRAIN;

EID: 34547207309     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07289     Document Type: Article

References (35)

1. Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, and Choyke P (2001). Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 12 (4), 301-308.
2. Choyke PL, Dwyer AJ, and Knopp MV (2003). Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 17 (5), 509-520.
3. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis L, and Gillies RJ (2005). Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7 (5), 475-485.
4. Padhani AR and Husband JE (2001). Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 56 (8), 607-620.
5. Yankeelov TE, Rooney WD, Li X, and Springer CS Jr (2003). Variation of the relaxographic "shutter-speed" for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magn Reson Med 50 (6), 1151-1169.
6. McPhail LD, McIntyre DJ, Ludwig C, Kestell P, Griffiths JR, Kelland LR, and Robinson SP (2006). Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 8 (3), 199-206.
7. Blasberg RG, Fenstermacher JD, and Patlak CS (1983). Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J Cereb Blood Flow Metab 3 (1), 8-32.
8. Groothuis DR, Fischer JM, Pasternak JF, Blasberg RG, Vick NA, and Bigner DD (1983). Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. Cancer Res 43 (7), 3368-3373.
9. Groothuis DR, Pasternak JF, Fischer JM, Blasberg RG, Bigner DD, and Vick NA (1983). Regional measurements of blood flow in experimental RG-2 rat gliomas. Cancer Res 43 (7), 3362-3367.
10. Kobayashi N, Allen N, Clendenon NR, and Ko LW (1980). An improved rat brain-tumor model. J Neurosurg 53 (6), 808-815.
11. 14C]-labeled tracers. Methods Mol Med 89, 177-190.
12. 2 maps acquired at 1.5 T. Hum Brain Mapp 25 (3), 353-359.
13. 2 mapping using gradient recalled acquisition in the steady state. Magn Reson Med 49 (3), 515-526.
14. Iannotti F, Fieschi C, Alfano B, Picozzi P, Mansi L, Pozzilli C, Punzo A, Del Vecchio G, Lenzi GL, Salvatore M, et al. (1987). Simplified, noninvasive PET measurement of blood - brain barrier permeability. J Comput Assist Tomogr 11 (3), 390-397.
15. Nakagawa H, Groothuis DR, Owens ES, Patlak CS, Pettigrew KD, and Glasberg RR (1988). Dexamethasone effects on vascular volume and tissue hematocrit in experimental RG-2 gliomas and adjacent brain. J Neuro-Oncol 6 (2), 157-168.
16. Bland JMand Altman DG (1996).Measurement error. BMJ 313 (7059), 744.
17. Bland JM and Altman DG (1996). Measurement error and correlation coefficients. BMJ 313 (7048), 41-42.
18. Bland JM and Altman DG (1999). Measuring agreement in method comparison studies. Stat Methods Med Res 8 (2), 135-160.
19. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, and Padhani AR (2002). Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 15 (2), 132-142.
20. Roberts C, Issa B, Stone A, Jackson A, Waterton JC, and Parker GJ (2006). Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging 23 (4), 554-563.
21. 125I]albumin distribution in experimental RG-2 gliomas and adjacent brain. J Cereb Blood Flow Metab 7 (6), 687-701.
22. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman SM, Steinberg SM, Liewehr DJ, et al. (2006). Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (5), 769-777.
23. Weinmann HJ, Brasch RC, Press WR, and Wesbey GE (1984). Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 142 (3), 619-624.
24. Aas AT, Brun A, Blennow C, Stromblad S, and Salford LG (1995). The RG2 rat glioma model. J Neuro-Oncol 23 (3), 175-183.
25. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, and Blasberg R (1995). RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 55 (9), 1902-1910.
26. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz E, Yeh BM, Lee FT Jr, et al. (2005). Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23 (24), 5464-5473.
27. Walker-Samuel S, Parker CC, Leach MO, and Collins DJ (2007). Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function. Phys Med Biol 52 (1), 75-89.
28. Jackson A, Jayson GC, Li KL, Zhu XP, Checkley DR, Tessier JJ, and Waterton JC (2003). Reproducibility of quantitative dynamic contrast enhanced MRI in newly presenting glioma. Br J Radiol 76 (903), 153-162.
29. Brix G, Semmler W, Port R, Schad LR, Layer G, and Lorenz WJ (1991). Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15 (4), 621-628.
30. Henderson E, Rutt BK, and Lee TY (1998). Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging 16 (9), 1057-1073.
31. Zhou R, Pickup S, Yankeelov TE, Springer CS Jr, and Glickson JD (2004). Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: effects of transcytolemmal water exchange. Magn Reson Med 52 (2), 248-257.
32. Barrett T, Kobayashi H, Brechbiel M, and Choyke PL (2006). Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol 60 (3), 353-366.
33. Turetschek K, Roberts TP, Floyd E, Preda A, Novikov V, Shames DM, Carter WO, and Brasch RC (2001). Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging 13 (6), 882-888.
34. de Lussanet QG, Langereis S, Beets-Tan RG, van Genderen MH, Griffioen AW, van Engelshoven JM, and Backes WH (2005). Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology 235 (1), 65-72.
35. Marzola P, Degrassi A, Calderan L, Farace P, Crescimanno C, Nicolato E, Giusti A, Pesenti E, Terron A, Sbarbati A. et al. (2004). In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 10 (2), 739-750.